Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Inc.
Advaxis Incorporated Receives List of Questions from the U.S. Food and Drug Administration
August 15th, 2008
Advaxis Inc., (OTCBB: ADXS), a developmental biotechnology company, received comments from the U. S. Food & Drug Administration (the "FDA") regarding its Investigational New Drug ("IND") application for Lovaxin C, the Company's lead drug candidate, which was filed with a proposed Phase II study for the treatment of Cervical Intraepithelial Neoplasia ("CIN"). The FDA's first written response letter, received last week, addressed preclinical, manufacturing, microbiologic, immunologic and clinical questions concerning Lovaxin C and its therapeutic use in CIN and cervical cancer caused by the sexually transmitted human papilloma virus ("HPV"). The FDA also requested...
Source: Health Business Week (2008-08-15)
|
